Definitive Contract HHSN266200400008C
Award Date 12/30/03
Potential Completion Date 12/29/08
Potential Value $13M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Hamilton, MT 59840, USA
Solicitation Procedures
Not listed
Number Of Offers Received
6
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $5,907,864.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Inimmune Corp, a biotechnology company based in Missoula, Montana. The contract is for the development of a synthetic AS01-like adjuvant system for influenza vaccines. This is not a set-aside contract. Inimmune Corp is a promising new biotechnology company with expertise in synthetic and process...
- This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
- This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
- This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...
- This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...
- The federal contract award HHSN272200800039C was a $8,394,390.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization, on September 30, 2008. The contract is part of NIAID's Adjuvant Discovery Program and is for biomedical research services. It has a cost-no-fee pricing type and an ultimate completion date of September 29, 2013. The contract was not set aside for any specific business...